Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Iwase Cosfa Co. Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This is assigned to 1 distinct examiner and 1 distinct art unit. NGUYEN, NGOC-ANH THI is the busiest examiner, with 1 pending office action. This single pending matter defines the current prosecution landscape for the entity within this technical field.
The 1 to 1 ratio between pending office actions and distinct examiners shows that the company's current prosecution is entirely concentrated under NGUYEN, NGOC-ANH THI. As the busiest examiner, she is responsible for the only active matter in the Biotechnology & Pharmaceuticals area. The involvement of 1 distinct art unit indicates that the technical review is focused within a single specialized group. This centralized prosecution means that the company is currently interacting with only 1 examiner and 1 art unit. Practitioners should note that there is no spread of matters across multiple officials, as the 1 pending action represents the entirety of the company's active workload. This focused activity suggests a specific patent objective for the current period, with the 1 pending office action being the sole focus of the company's efforts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NGUYEN, NGOC-ANH THI | 1 | 30.3% | +50.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18853872 | COSMETIC | NGUYEN, NGOC-ANH THI | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18853872 | COSMETIC | NGUYEN, NGOC-ANH THI | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18853872 | COSMETIC | NGUYEN, NGOC-ANH THI | 1615 | §102§112 | Non-Final OA | — | Pending | Oct 03, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialIwase Cosfa Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Ngoc-Anh Thi Nguyen has the most, with 1 of Iwase Cosfa Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
